NeuroSense Therapeutics Company Insiders
| NRSNW Stock | USD 0.21 0.01 5.00% |
NeuroSense Therapeutics employs about 18 people. The company is managed by 12 executives with a total tenure of roughly 42 years, averaging almost 3.0 years of service per executive, having 1.5 employees per reported executive. Recap of NeuroSense Therapeutics' management performance can provide insight into the venture performance.
NeuroSense |
NeuroSense Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (2.1964) % which means that it has lost $2.1964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.9484) %, meaning that it generated substantial loss on money invested by shareholders. NeuroSense Therapeutics' management efficiency ratios could be used to measure how well NeuroSense Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.NeuroSense Therapeutics Workforce Comparison
NeuroSense Therapeutics Ltd is regarded second in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 88.0. NeuroSense Therapeutics totals roughly 18.0 in number of employees claiming about 20% of equities under Health Care industry.
NeuroSense Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. NeuroSense Therapeutics Price Series Summation is a cross summation of NeuroSense Therapeutics price series and its benchmark/peer.
NeuroSense Therapeutics Notable Stakeholders
A NeuroSense Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NeuroSense Therapeutics often face trade-offs trying to please all of them. NeuroSense Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NeuroSense Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Yael Barak | VP Compliance | Profile | |
| Ferenc Tracik | Chief Officer | Profile | |
| Or Eisenberg | Chief Officer | Profile | |
| Alon BenNoon | CEO CoFounder | Profile | |
| Hagit Binder | Chief Officer | Profile | |
| Oron DVM | Chief Officer | Profile | |
| Ferenc MD | Chief Officer | Profile | |
| Shiran Zimri | Head Program | Profile | |
| Keren Pushett | Head HR | Profile | |
| Avital Pushett | Head Program | Profile | |
| Eidan Loushi | CRA | Profile | |
| Niva RussekBlum | Chief Officer | Profile |
About NeuroSense Therapeutics Management Performance
The success or failure of an entity such as NeuroSense Therapeutics often depends on how effective the management is. NeuroSense Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NeuroSense management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NeuroSense management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Neurosense Therapeutics is traded on NASDAQ Exchange in the United States.
Please note, the imprecision that can be found in NeuroSense Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NeuroSense Therapeutics Ltd. Check NeuroSense Therapeutics' Beneish M Score to see the likelihood of NeuroSense Therapeutics' management manipulating its earnings.
NeuroSense Therapeutics Workforce Analysis
Traditionally, organizations such as NeuroSense Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NeuroSense Therapeutics within its industry.NeuroSense Therapeutics Manpower Efficiency
Return on NeuroSense Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 626.7K | |
| Net Loss Per Executive | 940K |
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.